{"organizations": [], "uuid": "283ad98f1837e3323d67090bb97f548fff738eaf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-syros-announces-clinical-supply-ag/brief-syros-announces-clinical-supply-agreement-with-janssen-to-evaluate-sy-1425-idUSASB0BZFC", "country": "US", "domain_rank": 408, "title": "BRIEF-Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-02T15:17:00.000+02:00", "replies_count": 0, "uuid": "283ad98f1837e3323d67090bb97f548fff738eaf"}, "author": "", "url": "https://www.reuters.com/article/brief-syros-announces-clinical-supply-ag/brief-syros-announces-clinical-supply-agreement-with-janssen-to-evaluate-sy-1425-idUSASB0BZFC", "ord_in_thread": 0, "title": "BRIEF-Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425", "locations": [], "entities": {"persons": [{"name": "janssen", "sentiment": "negative"}], "locations": [{"name": "genomically", "sentiment": "none"}], "organizations": [{"name": "aml", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "syros pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 2, 2018 / 1:19 PM / in 9 minutes BRIEF-Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425 Reuters Staff 1 Min Read \nJan 2 (Reuters) - Syros Pharmaceuticals Inc: \n* SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS \n* SYROS PHARMACEUTICALS - JANSSEN TO SUPPLY DARATUMUMAB FOR COMBINATION DOSING COHORT IN SYROS’ ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425 \n* SYROS PHARMACEUTICALS - JANSSEN TO RECEIVE ACCESS TO DATA FROM COHORT EVALUATING SAFETY & EFFICACY OF SY-1425 IN COMBINATION WITH DARATUMUMAB FOR RESEARCH AND DEVELOPMENT \n* SYROS PHARMACEUTICALS - ‍EXPECTS TO BEGIN ENROLLING PATIENTS IN COMBINATION COHORT WITH DARATUMUMAB IN EARLY 2018​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-02T15:17:00.000+02:00", "crawled": "2018-01-02T15:36:35.024+02:00", "highlightTitle": ""}